RT Journal Article
SR Electronic
T1 Cost-effectiveness modelling of telehealth for patients with raised cardiovascular disease risk: evidence from a cohort simulation conducted alongside the Healthlines randomised controlled trial
JF BMJ Open
JO BMJ Open
FD British Medical Journal Publishing Group
SP e012355
DO 10.1136/bmjopen-2016-012355
VO 6
IS 9
A1 Dixon, Padraig
A1 Hollinghurst, Sandra
A1 Ara, Roberta
A1 Edwards, Louisa
A1 Foster, Alexis
A1 Salisbury, Chris
YR 2016
UL http://bmjopen.bmj.com/content/6/9/e012355.abstract
AB Objectives To investigate the long-term cost-effectiveness (measured as the ratio of incremental NHS cost to incremental quality-adjusted life years) of a telehealth intervention for patients with raised cardiovascular disease (CVD) risk.Design A cohort simulation model developed as part of the economic evaluation conducted alongside the Healthlines randomised controlled trial.Setting Patients recruited through primary care, and intervention delivered via telehealth service.Participants Participants with a 10-year CVD risk ≥20%, as measured by the QRISK2 algorithm, and with at least 1 modifiable risk factor, individually randomised from 42 general practices in England.Intervention A telehealth service delivered over a 12-month period. The intervention involved a series of responsive, theory-led encounters between patients and trained health information advisors who provided access to information resources and supported medication adherence and coordination of care.Primary and secondary outcome measures Cost-effectiveness measured by net monetary benefit over the simulated lifetime of trial participants from a UK National Health Service perspective.Results The probability that the intervention was cost-effective depended on the duration of the effect of the intervention. The intervention was cost-effective with high probability if effects persisted over the lifetime of intervention recipients. The probability of cost-effectiveness was lower for shorter durations of effect.Conclusions The intervention was likely to be cost-effective under a lifetime perspective.Trial registration number ISRCTN27508731; Results.